Company Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – Asfotase Alfa Granted Orphan Drug Designation in Japan

[Business Wire] – CHESHIRE, Conn.–(BUSINESSWIRE)– Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN – News) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation (ODD) to asfotase alfa for the . . . → Read More: Company Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – Asfotase Alfa Granted Orphan Drug Designation in Japan Similar Articles: Company Update (NYSE:PFE): Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO™ (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease Stock Update (NASDAQ:ALXN): Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft Function (DGF) after Kidney Transplantation Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Issues Voluntary Recall of Aranesp® (darbepoetin alfa) (500 mcg) Prefilled Syringes in Several Countries Outside of the United States Due to the Presence of Visible Particulates